Citations for: Toxnet: Megestrol Acetate

Entry Type
Name
Value
Parent Entry
Physical & Chemical Properties Data Field
Melting Point
BP: About 217° C
ChemIDPlus: 214° C
Megestrol Acetate (API)
Pharmacology Data Field
Bioavailability
Has not been evaluated.
Megestrol Acetate (API)
Metabolites
17α-Acetoxy-2α-hydroxy-6-methylpregna-4,6-diene-3,20-dione
N/A
Metabolites
17α-Acetoxy-6-hydroxymethylpregna-4,6-diene-3,20-dione
N/A
Metabolites
17α-Acetoxy-2α-hydroxy-6-hydroxymethylpregna-4,6-diene-3,20-dione
N/A
Physical & Chemical Properties Data Field
Storage Conditions
Tablets should be stored in well-closed containers at <40 °C, recommended 15-30 °C. Oral suspension should be stored in tight containers <= 25 °C.
Megestrol Acetate (API)
Pharmacology Data Field
Elimination Half-Life (t1/2)
Mean 34.2 h, range 13-104.9 h
Megestrol Acetate (API)
Pharmacology Data Field
Metabolism
Mainly metabolized by CYP3A4, but also by CYP3A5. Hepatic.
Megestrol Acetate (API)
Pharmacology Data Field
Excretion
Major route of elimination is through urine, minor route through feces.
Megestrol Acetate (API)
Pharmacology Data Field
Cmax
25-100 ng/mL from 50 mg oral dose
Megestrol Acetate (API)
Pharmacology Data Field
Tmax
2-5 h from 50 mg oral dose
Megestrol Acetate (API)
Pharmacology Data Field
Indications
Tablets: Palliative treatment of advanced carcinoma of the breast or endometrium. Should not be used in lieu of surgery, radiation, or chemotherapy, or other accepted procedures.
Oral suspension: anorexia, cachexia, or unexplained, significant weight loss in patients with AIDS.
Megestrol Acetate (API)